IP Library Granted Patent US 12,420,102
Granted Patent B2
US 12,420,102 · App. 17/491,756 · Granted Sep 23, 2025

System, device, and method for generating stimulation waveform having a paresthesia-inducing low-frequency component and a spread-spectrum high-frequency component

Inventors: Norbert Kaula (Arvada, CO); Yohannes Iyassu (Denver, CO); Scott Brainard (Columbus Heights, MN)
Assignee: Cirtec Medical Corporation
A61N1/37235A61N1/36021A61N1/36034A61N1/36071A61N1/36125A61N1/36132A61N1/36146A61N1/36171A61N1/37217A61N1/37247A61N1/36153A61N1/36157A61N1/36175A61N1/36185A61N1/3787
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,420,102
App. No.
17/491,756
Granted
Sep 23, 2025
Kind
B2
Abstract

A pulse generator includes charging circuitry configured to provide electrical power to the pulse generator. The pulse generator includes communication circuitry configured to conduct wireless telecommunications with external programming devices. The telecommunications contain programming instructions sent from the external programming devices. The pulse generator includes stimulation circuitry configured to generate electrical pulses based on the programming instructions. The electrical pulses include a first component that is paresthesia-inducing and a second component that is non-paresthesia-inducing.

Claims (60)

1. A pulse generator, comprising:

communication circuitry configured to receive programming instructions sent from one or more electronic programming devices; and

stimulation circuitry configured to generate electrical pulses based on the received programming instructions, wherein:

when viewed in a frequency domain, the electrical pulses have a tonic component and a spread-spectrum component different from the tonic component;

the tonic component and the spread-spectrum component are simultaneously viewable in the frequency domain; and

the spread-spectrum component spans a substantially wider frequency range than the tonic component in the frequency domain, wherein the spread-spectrum component comprises a plurality of non-periodic electrical pulses when viewed in a time domain, and wherein an amount of time between each adjacent pair of the non-periodic electrical pulses is variable.

2. The pulse generator of claim 1 , wherein when the electrical pulses are delivered to a patient:

the tonic component induces paresthesia; and

the spread-spectrum component does not induce paresthesia.

3. The pulse generator of claim 1 , wherein:

the tonic component has a fixed frequency.

4. The pulse generator of claim 1 , wherein: the spread-spectrum component corresponds to non-periodic electrical pulses when viewed in a time domain.

5. The pulse generator of claim 1 , wherein the amount of time between each adjacent pair of the non-periodic electrical pulses is defined by a pseudo-random number generator located within the stimulation circuitry.

6. The pulse generator of claim 1 , wherein:

the tonic component spans a first frequency range; and

the spread-spectrum component spans a second frequency range that is at least an order of magnitude larger than the first frequency range.

7. The pulse generator of claim 6 , wherein:

the first frequency range has a center frequency f1 that is below one kilo-hertz (kHz);

the second frequency range is defined by a lower frequency limit f2 and a higher frequency limit f3; and

the lower frequency limit f2 and the higher frequency limit f3 are each in a kHz-range.

8. The pulse generator of claim 7 , wherein the higher frequency limit f3 is several kHz larger than the lower frequency limit f2.

9. The pulse generator of claim 7 , wherein the center frequency f1 is several tens of hertz.

10. The pulse generator of claim 7 , wherein the center frequency f1 is several hundreds of hertz.

11. The pulse generator of claim 1 , wherein a magnitude of the tonic component is substantially greater than a magnitude of the spread-spectrum component.

12. A method, comprising:

receiving, via communication circuitry on a pulse generator, programming instructions from a programming device that is external to the pulse generator; and

generating, based on the received programming instructions, electrical pulses via stimulation circuitry on the pulse generator, wherein:

the electrical pulses have a fixed-frequency component and a spread-spectrum component;

the fixed-frequency component and the spread-spectrum component are simultaneously viewable in a frequency domain;

the spread-spectrum component spans a substantially wider frequency range than the fixed-frequency component in the frequency domain;

the spread-spectrum component comprises a plurality of non-periodic electrical pulses viewable in a time domain; and

an amount of time between each adjacent pair of the non-periodic electrical pulses is pseudo-randomly generated.

13. The method of claim 12 , further comprising: delivering the electrical pulses to a patient;

wherein:

the fixed-frequency component induces paresthesia when delivered to the patient; and

the spread-spectrum component does not induce paresthesia when delivered to the patient.

14. The method of claim 12 , wherein the generating comprises:

generating a plurality of pseudo-random numbers via a pseudo-random number generator; and

defining the amount of time between each adjacent pair of the non-periodic electrical pulses at least in part using the plurality of pseudo-random numbers.

15. The method of claim 12 , wherein a frequency range spanned by the spread-spectrum component is at least ten times wider than a frequency range spanned by the fixed-frequency component in the frequency domain.

16. The method of claim 12 , wherein:

a frequency of the fixed-frequency component is several tens of hertz; and

a lower limit of the spread-spectrum component is several kilo-hertz.

17. The method of claim 12 , wherein a magnitude of the fixed-frequency component is substantially greater than a magnitude of the spread-spectrum component.

18. A medical system, comprising:

an electronic programming device configured to generate programming instructions in response to user input; and

a pulse generator configured to generate electrical pulses based on the programming instructions;

wherein:

the electronic programming device or the pulse generator includes a pseudo-random number generator;

in a frequency spectrum, the electrical pulses simultaneously demonstrate at least a tonic component and a spread-spectrum component different from the tonic component;

the spread-spectrum component occupies a frequency range that is at least an order of magnitude wider than the tonic component in the frequency spectrum;

the spread-spectrum component comprises a plurality of pulses viewable in a time domain; and

an amount of time between each preceding pulse and a subsequent pulse of the plurality of pulses is defined by an output of the pseudo-random number generator.

19. The medical system of claim 18 , wherein:

the tonic component is configured to induce paresthesia in a patient;

the spread-spectrum component is configured to not induce paresthesia in the patient; and

an amplitude of the tonic component is greater than an amplitude of the spread-spectrum component.

20. The medical system of claim 18 , wherein in the time domain:

the tonic component corresponds to a plurality of first pulses having a fixed period between adjacent first pulses; and

the amount of time between each preceding pulse and the subsequent pulse of the plurality of pulses of the spread-spectrum component is different from the fixed period.

Assignments (3)
PATENT SECURITY AGREEMENT Recorded Jan 30, 2023
From: CIRTEC MEDICAL CORP.
To: BMO HARRIS BANK N.A., AS COLLATERAL AGENT
Reel/Frame 062559/0098 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2021
From: KAULA, NORBERT; IYASSU, YOHANNES; BRAINARD, SCOTT
To: NUVECTRA CORPORATION
Reel/Frame 057667/0757 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2021
From: NUVECTRA CORPORATION
To: CIRTEC MEDICAL CORPORATION
Reel/Frame 057681/0599 →
Continuity (3)
Continuation 15976618 · May 10, 2018
Provisional Application 62505209 · May 12, 2017
Related Publication 20220016431A1 · Jan 20, 2022
References Cited (53)
US 4338945A · Kosugi et al. · 1982 [cited by applicant]
US 6188929B1 · Giordano · 2001 [cited by applicant]
US 6501307B1 · Yen · 2002 [cited by applicant]
US 6631295B2 · Rubinstein et al. · 2003 [cited by applicant]
US 7047078B2 · Boggs, II et al. · 2006 [cited by applicant]
US 7228179B2 · Campen et al. · 2007 [cited by applicant]
US 7340302B1 · Falkenberg et al. · 2008 [cited by applicant]
US 7483747B2 · Gliner et al. · 2009 [cited by applicant]
US 7844339B2 · Buchner · 2010 [cited by applicant]
US 7983762B2 · Gliner et al. · 2011 [cited by applicant]
US 8301263B2 · Donofrio et al. · 2012 [cited by applicant]
US 8359102B2 · Alataris et al. · 2013 [cited by applicant]
US 8364273B2 · De Ridder · 2013 [cited by applicant]
US 8644941B2 · Rooney et al. · 2014 [cited by applicant]
US 8825166B2 · John · 2014 [cited by applicant]
US 8843209B2 · Wacnik et al. · 2014 [cited by applicant]
US 8914119B2 · Wu et al. · 2014 [cited by applicant]
US 9387325B1 · Min et al. · 2016 [cited by applicant]
US 9452294B2 · Kaula et al. · 2016 [cited by applicant]
US 9492667B1 · Kent et al. · 2016 [cited by applicant]
US 9533152B2 · Kilgard et al. · 2017 [cited by applicant]
US 9550063B2 · Wolf · 2017 [cited by applicant]
US 20030135248A1 · Stypulkowski · 2003 [cited by examiner]
US 20050015117A1 · Gerber · 2005 [cited by applicant]
US 20070027486A1 · Armstrong · 2007 [cited by applicant]
US 20070100377A1 · Armstrong et al. · 2007 [cited by applicant]
US 20070293917A1 · Thompson et al. · 2007 [cited by applicant]
US 20090204173A1 · Fang et al. · 2009 [cited by applicant]
US 20110009919A1 · Carbunaru et al. · 2011 [cited by applicant]
US 20110184486A1 · De Ridder · 2011 [cited by applicant]
US 20110184488A1 · De Ridder · 2011 [cited by examiner]
US 20120095524A1 · Nelson et al. · 2012 [cited by applicant]
US 20120203303A1 · Alataris · 2012 [cited by applicant]
US 20140277281A1 · Grandhe · 2014 [cited by applicant]
US 20150374986A1 · Bahmer · 2015 [cited by applicant]
US 20160001087A1 · Moffitt · 2016 [cited by applicant]
US 20160022992A1 · Franke et al. · 2016 [cited by applicant]
US 20160074663A1 · De Ridder · 2016 [cited by examiner]
US 20160158550A1 · Hou et al. · 2016 [cited by applicant]
US 20160175589A1 · Wingeier · 2016 [cited by applicant]
US 20160206877A1 · Hargrove · 2016 [cited by applicant]
US 20160367812A1 · De Ridder · 2016 [cited by examiner]
US 20180326220A1 · Kaula et al. · 2018 [cited by applicant]
EP 3103515A1 · 2016 [cited by examiner]
WO WO2015196164 · 2015 [cited by applicant]
WO WO2016086176 · 2016 [cited by applicant]
WO WO2018035521A1 · 2018 [cited by applicant]
De Ridder, Dirk, et al., “Mimicking the Brain: Evaluation of St Jude Medical's Prodigy Chronic Pain System with Burst Technology”, Expert Rev. Med. Devices, vol. 12, No. 2, pp. 143-150 (Dec. 2015). [cited by applicant]
De Ridder, Dirk, et al., “A 2-Center Comparative Study on Tonic Versus Burst Spinal Cord Stimulation Amount of Responders and Amount of Pain Suppression”, Clin. J. Pain, vol. 31, No. 5, pp. 433-437 (May 2015). [cited by applicant]
Joos, Kathleen, et al., “The Differential Effect of Low- Versus High-Frequency Random Noise Stimulation in the Treatment of Tinnitus”, Exp. Brain Res., vol. 233, pp. 1433-1440 (Feb. 2015). [cited by applicant]
Freescale Semiconductor, Inc., “i.MX51 Applications Processors for Consumer and Industrial Products,” Data Sheet Technical Data, Document No. IMX51CEC, Rev. 4 (Aug. 2010), 200 pages. [cited by applicant]
Texas Instruments, Inc., “Mixed Signal Microcontroller,” brochure, MSP430G2x32, MSP430G2x02, SLAS723 (Dec. 2010), 53 pages. [cited by applicant]
European Patent Office, “European Search Report”, Application No. 18172740.5, mailed Sep. 10, 2018, 9 pages. [cited by applicant]